The Japanese group Fujifilm has started a clinical trial to test the effectiveness of its influenza drug Avigan (favipiravir) to treat patients with the new coronavirus, after encouraging results from other studies conducted in China on this product. “The trial will be conducted on 100 patients by the end of June“In Tokyo, said Wednesday a spokesman for Fujifilm, known to the general public for its office and photography products, but which is also present in the medical sector.
“We will collect data, analyze it and request approval“Later if this so-called phase III clinical trial proves conclusive,” he added.
Avigan will be given for up to 14 days to patients aged 20 to 74 years, all at a mild stage of viral pneumonia. Pregnant women will be excluded from the study because of the risk of side effects. The move comes after Japanese Prime Minister Shinzo Abe said last weekend that his government will initiate regulatory procedures to get Avigan approved to treat the new coronavirus.
»SEE ALSO – Dr. Mascret answers: what do we really know about the effectiveness of chloroquine on Covid-19?